TY  - JOUR
AU  - Claus, Rainer
AU  - Lucas, David M
AU  - Ruppert, Amy S
AU  - Williams, Katie E
AU  - Weng, Daniel
AU  - Patterson, Kara
AU  - Zucknick, Manuela
AU  - Oakes, Christopher C
AU  - Rassenti, Laura Z
AU  - Greaves, Andrew W
AU  - Geyer, Susan
AU  - Wierda, William G
AU  - Brown, Jennifer R
AU  - Gribben, John G
AU  - Barrientos, Jacqueline C
AU  - Rai, Kanti R
AU  - Kay, Neil E
AU  - Kipps, Thomas J
AU  - Shields, Peter
AU  - Zhao, Weiqiang
AU  - Grever, Michael R
AU  - Plass, Christoph
AU  - Byrd, John C
TI  - Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
JO  - Blood
VL  - 124
IS  - 1
SN  - 1528-0020
CY  - Stanford, Calif.
PB  - HighWire Press
M1  - DKFZ-2017-00388
SP  - 42 - 48
PY  - 2014
AB  - ZAP-70 methylation 223 nucleotides downstream of transcription start (CpG+223) predicts outcome in chronic lymphocytic leukemia (CLL), but its impact relative to CD38 and ZAP-70 expression or immunoglobulin heavy chain variable region (IGHV) status is uncertain. Additionally, standardizing ZAP-70 expression analysis has been unsuccessful. CpG+223 methylation was quantitatively determined in 295 untreated CLL cases using MassARRAY. Impact on clinical outcome vs CD38 and ZAP-70 expression and IGHV status was evaluated. Cases with low methylation (<20
KW  - Biomarkers, Tumor (NLM Chemicals)
KW  - Immunoglobulin Variable Region (NLM Chemicals)
KW  - ZAP-70 Protein-Tyrosine Kinase (NLM Chemicals)
KW  - ZAP70 protein, human (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:24868078
C2  - pmc:PMC4125353
DO  - DOI:10.1182/blood-2014-02-555722
UR  - https://inrepo02.dkfz.de/record/119761
ER  -